The Cochrane Library: Cochrane Database of Systematic Reviews

DOI: 10.1002/14651858

Reviews/Protocols listed by Cochrane Review Group


  1. Cochrane Acute Respiratory Infections Group
  2. Cochrane Airways Group
  3. Cochrane Anaesthesia Group
  4. Cochrane Back Group
  5. Cochrane Bone, Joint and Muscle Trauma Group
  6. Cochrane Breast Cancer Group
  7. Cochrane Childhood Cancer Group
  8. Cochrane Colorectal Cancer Group
  9. Cochrane Consumers and Communication Group
  10. Cochrane Cystic Fibrosis and Genetic Disorders Group
  11. Cochrane Dementia and Cognitive Improvement Group
  12. Cochrane Depression, Anxiety and Neurosis Group
  13. Cochrane Developmental, Psychosocial and Learning Problems Group
  14. Cochrane Drugs and Alcohol Group
  15. Cochrane Ear, Nose and Throat Disorders Group
  16. Cochrane Effective Practice and Organisation of Care Group
  17. Cochrane Epilepsy Group
  18. Cochrane Eyes and Vision Group
  19. Cochrane Fertility Regulation Group
  20. Cochrane Gynaecological Cancer Group
  21. Cochrane Haematological Malignancies Group
  22. Cochrane Heart Group
  23. Cochrane Hepato-Biliary Group
  24. Cochrane HIV/AIDS Group
  25. Cochrane Hypertension Group
  26. Cochrane Incontinence Group
  27. Cochrane Infectious Diseases Group
  28. Cochrane Inflammatory Bowel Disease and Functional Bowel Disorders Group
  29. Cochrane Injuries Group
  30. Cochrane Lung Cancer Group
  31. Cochrane Menstrual Disorders and Subfertility Group
  32. Cochrane Metabolic and Endocrine Disorders Group
  33. Cochrane Methodology Review Group
  34. Cochrane Movement Disorders Group
  35. Cochrane Multiple Sclerosis and Rare Diseases of the Central Nervous System Group
  36. Cochrane Musculoskeletal Group
  37. Cochrane Neonatal Group
  38. Cochrane Neuromuscular Disease Group
  39. Cochrane Occupational Safety and Health Group
  40. Cochrane Oral Health Group
  41. Cochrane Pain, Palliative and Supportive Care Group
  42. Cochrane Peripheral Vascular Diseases Group
  43. Cochrane Pregnancy and Childbirth Group
  44. Cochrane Prostatic Diseases and Urologic Cancers Group
  45. Cochrane Public Health Group
  46. Cochrane Renal Group
    1. About this group
    2. Reviews
      1. Aldosterone antagonists for preventing the progression of chronic kidney diseaseReview
      2. Alpha-blockers as medical expulsive therapy for ureteral stonesReview
      3. Altered dietary salt intake for preventing and treating diabetic kidney diseaseReview
      4. Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists for preventing the progression of diabetic kidney diseaseReview
      5. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for adults with early (stage 1 to 3) non-diabetic chronic kidney diseaseReview
      6. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for preserving residual kidney function in peritoneal dialysis patientsReview
      7. Antibiotic duration for treating uncomplicated, symptomatic lower urinary tract infections in elderly womenReview
      8. Antibiotic prophylaxis for preventing post solid organ transplant tuberculosisReview
      9. Antibiotics for acute pyelonephritis in childrenReview
      10. Antibiotics for preventing recurrent urinary tract infection in non-pregnant womenReview
      11. Antibiotics for treating lower urinary tract infection in childrenReview
      12. Antibody induction therapy for lung transplant recipientsReview
      13. Antifungal agents for preventing fungal infections in solid organ transplant recipientsReview
      14. Antihypertensive agents for preventing diabetic kidney diseaseReview
      15. Antihypertensive treatment for kidney transplant recipientsReview
      16. Antimicrobial agents for preventing peritonitis in peritoneal dialysis patientsReview
      17. Antimicrobial agents for treating uncomplicated urinary tract infection in womenReview
      18. Antioxidants for chronic kidney diseaseReview
      19. Antiplatelet agents for chronic kidney diseaseReview
      20. Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipientsReview
      21. Atrial natriuretic peptide for preventing and treating acute kidney injuryReview
      22. Bicarbonate versus lactate solutions for acute peritoneal dialysisReview
      23. Biocompatible dialysis fluids for peritoneal dialysisReview
      24. Biocompatible hemodialysis membranes for acute renal failureReview
      25. Calcimimetics for secondary hyperparathyroidism in chronic kidney disease patientsReview
      26. Calcium channel blockers for preventing acute tubular necrosis in kidney transplant recipientsReview
      27. Cardiac testing for coronary artery disease in potential kidney transplant recipientsReviewDiagnostic
      28. Catheter type, placement and insertion techniques for preventing peritonitis in peritoneal dialysis patientsReview
      29. Cellulose, modified cellulose and synthetic membranes in the haemodialysis of patients with end-stage renal diseaseReview
      30. Chinese herbal medicine Huangqi type formulations for nephrotic syndromeReview
      31. Continuous ambulatory peritoneal dialysis (CAPD) versus hospital or home haemodialysis for end-stage renal disease in adultsReview
      32. Continuous ambulatory peritoneal dialysis versus automated peritoneal dialysis for end-stage renal diseaseReview
      33. Continuous renal replacement therapy (CRRT) for rhabdomyolysisReview
      34. Correction of chronic metabolic acidosis for chronic kidney disease patientsReview
      35. Corticosteroid therapy for nephrotic syndrome in childrenReview
      36. Cranberries for preventing urinary tract infectionsReview
      37. Cranberries for treating urinary tract infectionsReview
      38. Cytomegalovirus prophylaxis with antiviral agents for solid organ transplantationReviewWithdrawn
      39. Darbepoetin for the anaemia of chronic kidney diseaseReview
      40. Dietary interventions for preventing complications in idiopathic hypercalciuriaReview
      41. Double bag or Y-set versus standard transfer systems for continuous ambulatory peritoneal dialysis in end-stage kidney diseaseReviewNew Search
      42. Duration of antibacterial treatment for uncomplicated urinary tract infection in womenReview
      43. Early referral to specialist nephrology services for preventing the progression to end-stage kidney diseaseReview
      44. Education programmes for people with diabetic kidney diseaseReview
      45. Effects of nonsteroidal anti-inflammatory drugs on postoperative renal function in adults with normal renal functionReview
      46. Emergency interventions for hyperkalaemiaReview
      47. Exercise training for adults with chronic kidney diseaseReview
      48. Extracorporeal shock wave lithotripsy (ESWL) versus percutaneous nephrolithotomy (PCNL) or retrograde intrarenal surgery (RIRS) for kidney stonesReview
      49. Extracorporeal shock wave lithotripsy (ESWL) versus ureteroscopic management for ureteric calculiReview
      50. Fish oil for kidney transplant recipientsReview
      51. Fluids and diuretics for acute ureteric colicReview
      52. Frequency of administration of erythropoiesis-stimulating agents for the anaemia of end-stage kidney disease in dialysis patientsReview
      53. Growth hormone for children with chronic kidney diseaseReview
      54. Haemodiafiltration, haemofiltration and haemodialysis for end-stage kidney diseaseReview
      55. Haemoglobin and haematocrit targets for the anaemia of chronic kidney diseaseReview
      56. Heparin and related substances for preventing diabetic kidney diseaseReview
      57. High-flux versus low-flux membranes for end-stage kidney diseaseReview
      58. HMG CoA reductase inhibitors (statins) for dialysis patientsReview
      59. HMG CoA reductase inhibitors (statins) for kidney transplant recipientsReview
      60. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysisReview
      61. Human albumin for intradialytic hypotension in haemodialysis patientsReview
      62. Hydroxyethyl starch (HES) versus other fluid therapies: effects on kidney functionReview
      63. Immunoglobulins, vaccines or interferon for preventing cytomegalovirus disease in solid organ transplant recipientsReview
      64. Immunosuppressive agents for treating IgA nephropathyReview
      65. Immunosuppressive treatment for focal segmental glomerulosclerosis in adultsReview
      66. Immunosuppressive treatment for idiopathic membranous nephropathy in adults with nephrotic syndromeReview
      67. Interleukin 2 receptor antagonists for kidney transplant recipientsReview
      68. Intermittent versus continuous renal replacement therapy for acute renal failure in adultsReview
      69. Interventions for bone disease in children with chronic kidney diseaseReview
      70. Interventions for covert bacteriuria in childrenReview
      71. Interventions for erythropoietin-resistant anaemia in dialysis patientsReview
      72. Interventions for haemolytic uraemic syndrome and thrombotic thrombocytopenic purpuraReview
      73. Interventions for HIV-associated nephropathyReview
      74. Interventions for idiopathic steroid-resistant nephrotic syndrome in childrenReview
      75. Interventions for minimal change disease in adults with nephrotic syndromeReview
      76. Interventions for preventing and treating kidney disease in Henoch-Schönlein Purpura (HSP)Review
      77. Interventions for preventing bone disease in kidney transplant recipientsReview
      78. Interventions for preventing infection in nephrotic syndromeReview
      79. Interventions for preventing infectious complications in haemodialysis patients with central venous cathetersReview
      80. Interventions for primary vesicoureteric refluxReview
      81. Interventions for renal vasculitis in adultsReview
      82. Interventions for treating sexual dysfunction in patients with chronic kidney diseaseReview
      83. Laparoscopic versus open nephrectomy for live kidney donorsReview
      84. Lipid-lowering agents for nephrotic syndromeReview
      85. Long-term antibiotics for preventing recurrent urinary tract infection in childrenReview
      86. Low protein diets for chronic kidney disease in non diabetic adultsReview
      87. Methenamine hippurate for preventing urinary tract infectionsReview
      88. Modes of administration of antibiotics for symptomatic severe urinary tract infectionsReview
      89. Non-corticosteroid immunosuppressive medications for steroid-sensitive nephrotic syndrome in childrenReview
      90. Non-immunosuppressive treatment for IgA nephropathyReview
      91. Nonsteroidal anti-inflammatory drugs (NSAIDS) versus opioids for acute renal colicReview
      92. Nutritional support for acute kidney injuryReview
      93. Oestrogens for preventing recurrent urinary tract infection in postmenopausal womenReview
      94. Parenteral versus oral iron therapy for adults and children with chronic kidney diseaseReview
      95. Pentoxifylline for diabetic kidney diseaseReview
      96. Percussion, diuresis, and inversion therapy for the passage of lower pole kidney stones following shock wave lithotripsyReview
      97. Pharmacological interventions for preventing complications in idiopathic hypercalciuriaReview
      98. Phosphate binders for preventing and treating bone disease in chronic kidney disease patientsReview
      99. Physical measures for treating depression in dialysis patientsReview
      100. Polyclonal and monoclonal antibodies for treating acute rejection episodes in kidney transplant recipientsReview
      101. Pre-emptive treatment for cytomegalovirus viraemia to prevent cytomegalovirus disease in solid organ transplant recipientsReview
      102. Prostaglandin E1 for preventing the progression of diabetic kidney diseaseReview
      103. Protein restriction for children with chronic kidney diseaseReview
      104. Psychosocial interventions for depression in dialysis patientsReview
      105. Quinolones for uncomplicated acute cystitis in womenReview
      106. Recombinant human erythropoietin for chronic renal failure anaemia in pre-dialysis patientsReview
      107. Rheum officinale (a traditional Chinese medicine) for chronic kidney diseaseReview
      108. Routine intraoperative ureteric stenting for kidney transplant recipientsReview
      109. Short versus standard duration oral antibiotic therapy for acute urinary tract infection in childrenReview
      110. Sodium bicarbonate supplements for treating acute kidney injuryReview
      111. Steroid avoidance or withdrawal for kidney transplant recipientsReview
      112. Steroid avoidance or withdrawal for pancreas and pancreas with kidney transplant recipientsReviewNew
      113. Tacrolimus versus cyclosporin as primary immunosuppression for kidney transplant recipientsReview
      114. Tacrolimus versus cyclosporin as primary immunosuppression for lung transplant recipientsReview
      115. Target of rapamycin inhibitors (TOR-I; sirolimus and everolimus) for primary immunosuppression in kidney transplant recipientsReview
      116. Teicoplanin versus vancomycin for proven or suspected infectionReview
      117. Thyroid hormones for acute kidney injuryReview
      118. Tidal versus other forms of peritoneal dialysis for acute kidney injuryReview
      119. Topical corticosteroids for treating phimosis in boysReviewNew
      120. Treatment for lupus nephritisReview
      121. Treatment for peritoneal dialysis-associated peritonitisReview
      122. Tripterygium wilfordii Hook F (a traditional Chinese medicine) for primary nephrotic syndromeReview
      123. Ultrasound use for the placement of haemodialysis cathetersReview
      124. Vitamin D compounds for people with chronic kidney disease not requiring dialysisReview
      125. Vitamin D compounds for people with chronic kidney disease requiring dialysisReview
      126. Water for preventing urinary stonesReview
    3. Protocols
      1. Acetylcysteine for preventing contrast-induced nephropathyProtocolNew
      2. Acupuncture and related interventions for the symptoms of chronic kidney diseaseProtocol
      3. Adjunctive medical expulsive therapy for kidney and ureteral stone fragments following shock wave lithotripsyProtocol
      4. Advance care planning for haemodialysis patientsProtocol
      5. Altered dietary salt intake for chronic kidney diseaseProtocol
      6. Amphotericin B deoxycholate versus liposomal amphotericin B: effects on kidney functionProtocol
      7. Analgesia for patients undergoing shockwave lithotripsy for urinary stonesProtocol
      8. Androgens for the anaemia of chronic kidney disease in adultsProtocol
      9. Antibiotics for asymptomatic bacteriuriaProtocol
      10. Antibody immunosuppression for pancreas and kidney-pancreas transplant recipientsProtocol
      11. Anticoagulants and antiplatelet agents for preventing central venous haemodialysis catheter malfunction in patients with end-stage kidney diseaseProtocol
      12. Antihypertensive agents for children with chronic kidney diseaseProtocol
      13. Antimicrobial lock solutions for preventing catheter-related infections in haemodialysisProtocol
      14. Aspiration and sclerotherapy versus hydrocoelectomy for treating hydrocoelesProtocol
      15. Belatacept for kidney transplant recipientsProtocol
      16. Bicarbonate versus lactate solutions for acute haemodialysisProtocol
      17. Calcineurin inhibitor withdrawal or tapering for kidney transplant recipientsProtocol
      18. Calcium channel blockers as medical expulsive therapy for ureteric stonesProtocol
      19. Calcium channel blockers for people with chronic kidney disease requiring dialysisProtocol
      20. Chinese herbal medicine for treating recurrent urinary tract infections in womenProtocol
      21. Chinese medicinal herbs for diabetic kidney diseaseProtocol
      22. Citrate salts for preventing and treating kidney stonesProtocol
      23. Clinical and physical signs for identification of impending and current water-loss dehydration in older peopleProtocolDiagnostic
      24. Continuous erythropoiesis receptor activator (CERA) for the anaemia of chronic kidney diseaseProtocol
      25. Cordyceps sinensis (a Chinese medicinal herb) for treating chronic kidney diseaseProtocol
      26. Cordyceps sinensis (a traditional Chinese medicine) for kidney transplant recipientsProtocol
      27. Dialysate sodium levels for chronic haemodialysisProtocol
      28. Dietary interventions for lowering cholesterol in dialysis patientsProtocol
      29. Dietary interventions for mineral and bone disorder in people with chronic kidney diseaseProtocol
      30. Dimercaptosuccinic acid scan versus ultrasound in screening for vesicoureteral reflux among children with urinary tract infectionsProtocolDiagnostic
      31. Direct renin inhibitors for preventing the progression of diabetic kidney diseaseProtocol
      32. Diuretics for treating oedema in nephrotic syndromeProtocol
      33. Donor organ preservation techniques for kidney transplantationProtocol
      34. Early versus delayed erythropoietin for the anaemia of end-stage kidney diseaseProtocol
      35. Effects of peri-operative nonsteroidal anti-inflammatory drugs on postoperative kidney function for adults with normal kidney functionProtocolNew
      36. Erythropoiesis stimulating agents for anaemia in adults with chronic kidney disease: a network meta-analysisProtocol
      37. Fenoldopam for preventing and treating acute kidney injuryProtocol
      38. Glucose lowering therapies for chronic kidney disease and kidney transplantationProtocol
      39. Glucose targets for preventing diabetic kidney disease and its progressionProtocol
      40. Haemodialysis duration, frequency and intensity for end-stage kidney diseaseProtocol
      41. HMG CoA reductase inhibitors (statins) for preventing acute kidney injury after surgical procedures requiring cardiac bypassProtocol
      42. Home versus in-centre haemodialysis for end-stage kidney diseaseProtocol
      43. Human albumin infusion for treating oedema in people with nephrotic syndromeProtocol
      44. Intensity of continuous renal replacement therapy for acute kidney injuryProtocol
      45. Interventions for chronic kidney disease-associated restless legs syndromeProtocol
      46. Interventions for chronic non-hypovolaemic hypotonic hyponatraemiaProtocol
      47. Interventions for dialysis patients with hepatitis C virus (HCV) infectionProtocol
      48. Interventions for increasing solid organ donor registrationProtocol
      49. Interventions for infected cysts in people with autosomal dominant polycystic kidney diseaseProtocol
      50. Interventions for lowering plasma homocysteine levels in dialysis patientsProtocol
      51. Interventions for lowering plasma homocysteine levels in kidney transplant recipientsProtocol
      52. Interventions for post-transplant anaemia in kidney transplant recipientsProtocol
      53. Interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapyProtocol
      54. Interventions for preventing intradialytic hypotension in haemodialysis patientsProtocol
      55. Interventions for preventing the progression of autosomal dominant polycystic kidney diseaseProtocol
      56. Interventions for treating urinary stones in childrenProtocol
      57. Interventions for undescended testes in childrenProtocol
      58. Ischaemic preconditioning for the reduction of renal ischaemia reperfusion injuryProtocol
      59. Isolation as a strategy for controlling the transmission of hepatitis C virus (HCV) infection in haemodialysis unitsProtocol
      60. Laparoendoscopic single-site donor nephrectomy (LESS-N) versus standard laparoscopic donor nephrectomyProtocol
      61. Loop diuretics for patients receiving blood transfusionsProtocol
      62. Magnesium-based interventions for people with chronic kidney diseaseProtocol
      63. Medical and dietary interventions for preventing recurrent urinary stones in childrenProtocolNew
      64. Mycophenolic acid versus azathioprine as primary immunosuppression for kidney transplant recipientsProtocol
      65. Nonsteroidal anti-inflammatory drugs (NSAIDs) and non-opioids for acute renal colicProtocol
      66. Normal saline versus lower-chloride solutions for kidney transplantationProtocol
      67. Oral adsorbents for preventing or delaying the progression of chronic kidney diseaseProtocol
      68. Pharmacological interventions for preventing contrast-induced nephropathyProtocol
      69. Pharmacological interventions for treating acute hyperkalaemia in adultsProtocol
      70. Polyclonal and monoclonal antibodies for induction therapy in kidney transplant recipientsProtocol
      71. Pre-emptive correction for haemodialysis arteriovenous access stenosisProtocol
      72. Preoperative vascular access evaluation for haemodialysis patientsProtocol
      73. Probiotics for preventing urinary tract infection in people with neuropathic bladderProtocol
      74. Probiotics for preventing urinary tract infections in adults and childrenProtocol
      75. Procalcitonin, C-reactive protein, and erythrocyte sedimentation rate for the diagnosis of acute pyelonephritis in childrenProtocolDiagnostic
      76. Radix Astragali (a Chinese medicinal herb) for treating chronic kidney diseaseProtocol
      77. Reduction of dialysate temperature for intradialytic hypotension during haemodialysisProtocol
      78. Renal replacement therapy for preventing contrast-induced nephropathyProtocol
      79. Screening with urinary dipsticks for reducing morbidity and mortalityProtocol
      80. Subcutaneous versus intravenous erythropoietin for long-term dialysis patientsProtocol
      81. Surgery versus non-surgical management for unilateral ureteric-pelvic junction obstruction in childrenProtocol
      82. Tacrolimus versus cyclosporin for simultaneous pancreas-kidney transplant recipientsProtocolWithdrawn
      83. Target of rapamycin inhibitors (TORi) as maintenance immunosuppression for kidney transplant recipientsProtocol
      84. Timing of continuous renal replacement therapy initiation for acute kidney injuryProtocol
      85. Tubeless versus standard percutaneous nephrolithotomy for treating kidney stonesProtocol
      86. Upper limb exercise for haemodialysis fistula surgeryProtocol
      87. Uric acid lowering therapies for preventing or delaying the progression of chronic kidney diseaseProtocol
      88. Urinary alkalisation for uncomplicated urinary tract infectionProtocol
      89. Vascular access type for patients on chronic haemodialysisProtocol
      90. Vitamin B and/or its derivatives for diabetic kidney diseaseProtocol
  47. Cochrane Schizophrenia Group
  48. Cochrane Sexually Transmitted Infections Group
  49. Cochrane Skin Group
  50. Cochrane Stroke Group
  51. Cochrane Tobacco Addiction Group
  52. Cochrane Upper Gastrointestinal and Pancreatic Diseases Group
  53. Cochrane Wounds Group

SEARCH